IL32 (interleukin-32) is a proinflammatory cytokine. It is expressed in 9 unique isoforms - IL-32a, ß, ?, d, e, ?, ?, s and ?. Initially it was called as the natural killer induced transcript 4 (NK4).
Synonyms: Anti-ALDH7; Anti-NK4; Anti-TAIF; Anti-TAIFb; Anti-TAIFd; Anti-interleukin 32
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: IL32 (interleukin-32) helps in the production of microbicidal molecules. It might also be associated with the phagocytosis of parasites. It can direct the acquired immune response by promoting the differentiation of monocytes into dendritic cells. It plays some major roles in antimicrobial pathways, cancer, and autoimmune diseases, including rheumatoid arthritis (RA), myasthenia gravis, and giant cell arteritis. IL32 is considered as a therapeutic target to block continuous inflammation and pathologies related to it in the HIV-infected population.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC